Neoplastic Disorder

8 Drugs classified under this biological system

Androgen Biosynthesis Inhibitor. Abiraterone Acetate 250 mg.
Tab 120 X 250 mg
1000 mg/d (4 tab.), once/d in comb. with oral prednisone 5 mg (twice/d for metast. CRPC and once/d for High risk mHSPC)
In comb. with prednisone for tmt. of metast. castr.-resist. prostate cancer (CRPC)
newly diagn. high risk metast. hormone-sensit. prostate
cancer (mHSPC) in adlt men in comb. with androgen depriv. ther.(ADT).  
C/I: Hypersens./Women/Sev. liver damage/In comb. with Ra-223

Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml.
mAb linked to DXd, an exatecan deriv. and a
topoisomerase I inhibit.
Vial, 100 mg. Powd. for concentr. for sol. for inf.
 Breast or Lung cancer: 5.4 mg/kg bw once every 21 days
Gastric cancer: 6.4 mg/kg once every 21 days.
Do not substitute with trastuzumab or ado-trastuzumab emtansine.
HER2-Posit. Metast. Breast Cancer ; HER2-Low Metast. Breast Cancer; Unresect. or Metast. HER2-Mutant Non-Small Cell Lung Cancer; Locally Adv. or Metast. Gastric Cancer. See Lit
C/I:  Hypersens.

Monoclonal Antibody. Trastuzumab 150 mg, Trastuzumab 420 mg.
Vial:Pwd. for conc. for sol for infus.
Load: 4-8 mg/kg BW
Maint. 2-6 mg/kg BW weekly or at 3 weekly interval, see lit.
Tmt. of pts. with metast. breast cancer who have tumours that overexpress HER2; 1. As a sgle. agent, for the tmt. of those pts. who have received one or more chemother. regimens for their metast. dis..2. In combin. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metastatic dis..3. In comb. with an aromatase inhib. for tmt. of postmenopausal ptt. with hne.-receptor posit. metast. breast cancer. See Lit
C/I: Hypersens. Sev. dyspnea at rest.

Human Monoclonal Antibody, Immunoglobulins. Durvalumab 50 mg/ml.
Vial:  Sol for inf.120/500 mg
Dosage and freq. depend on patient weight, disease type and monoor combined ther. See lit.
Urothelial Carcinoma: for pts with PD-L1 high (Tumor cell ≥25% or IC ≥25%) locally adv. or metast. urothelial carcinoma who:
- have dis. progr. during or following platinum-contain. chemother
. - have dis. progr. within 12 months of neoadj. or adj. tmt with platinum cont. chemother..
Non-Small Cell Lung Cancer - for pts with unresect. Stage III non-small cell lung cancer (NSCLC) whose dis. has not progr. following concurr.platinum-based chemother. and radiation ther.- in comb. with tremelimumab and platinum-based chemother. for the first-line tmt. of adlts with metast. NSCLC with no sensit. EGFR mutat. or ALK pos. mut..
Small Cell Lung Cancer, in combin. with etoposide and either carboplatin or cisplatin, for the first-line tmt. of adlt pts. with extens.-stage small cell lung cancer (ES-SCLC).
Biliary Tract Cancers: in comb. with gemcitabine and cisplatin for the first-line tmt of adlts with locally adv., unresect., or metast. biliary tract cancer (BTC).
Hepatocellular Carcinoma: in comb. with tremelimumab for the first line tmt of adlts with adv. or unresect. hepatocellular carcinoma (HCC).
C/I:  Hypersens.

Engineered Autologous T Cell Immunotherapy product. Tisagenlecleucel .
Dispers. for IV inf.  cont. 10-30 ml or 30-50 ml.
Dosage in paed. and young adlt. CD19+ B-cell ALL pts. - For pts.  under 50 kg : 0.2 to 5 x 10⁶ CAR-posit. viable T cells/kg BW. - For pts. above 50 kg: 0.1 to 2.5 x 10⁸ CAR-positive viable T cells (non-weight based). Dosage in adlt. DLBCL and FL pts. - 0.6 to 6.0 x 10⁸ CAR-posit. viable T cells (non-weight based).
Paed. and young adlt. pts. up to and incl. 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) refract., in relapse post-transpl. or in second or later relapse. – Adlt. pts. with relapsed or refract. diffuse large B-cell lymphoma (DLBCL) after two or more lines of syst. ther. Limit of Use: not for tmt. of pts. with prim. or second. CNS lymphoma- Adlt. pts. with relapsed or refract. follicular lymphoma (FL) after two or more lines of syst. ther.
C/I: Hypersens. Also consider C/I of the lymphodepleting chemother.

Anti-Androgen. Darolutamide 300 mg.
FC Tab X 112
600 mg (two tab. of 300 mg) taken 2Xd, equiv. to a total dly dose of 1200 mg
In combin. with ADT for the tmt. of adlt. men with non- metast. castr. resist. prostate cancer (nmCRPC) at high risk of develop. metast. dis. Indicat. for the tmt. of adlt. ptts. with metast. horm.-sensit. prostate cancer (mHSPC) in combin. with docetaxel.
C/I:  Hypersens. Women who are or may become pregn.